
IGC Stock Forecast & Price Target
IGC Analyst Ratings
Bulls say
IGC Pharma Inc is positioned favorably due to its ongoing development of investigational drug assets targeting Alzheimer's disease, which have shown potential effectiveness in addressing key hallmarks of the condition. The company's current valuation appears attractive, supported by a net present value analysis indicating significant upside potential from its current share price. Additionally, the anticipated release of positive data from ongoing studies is expected to act as a catalyst for further interest and investment in the stock.
Bears say
IGC Pharma Inc. reported a net loss of $1.6 million, resulting in earnings per share (EPS) of $(0.02), which aligns with prior estimates but underscores ongoing financial challenges. The company faces considerable risks, including balance sheet and liquidity concerns, potential failures in clinical trials for its investigational drug assets, and challenges in obtaining regulatory approvals and commercialization. Additionally, external factors such as macroeconomic changes and competition further complicate its financial outlook, limiting investor confidence in the stock’s future performance.
This aggregate rating is based on analysts' research of India Globalization Capital and is not a guaranteed prediction by Public.com or investment advice.
IGC Analyst Forecast & Price Prediction
Start investing in IGC
Order type
Buy in
Order amount
Est. shares
0 shares